Research
FORUM TRANSCRIPT

CRO Sector Q2 2023 Update – Industry-wide Developments & Competitive Differentiation

  • Private Equity
  • Healthcare
  • North America
PREMIUM

Specialist

Former Director at Cytel Inc

Agenda

  • Significant trends and developments within a capital-constrained CRO (contract research organisation) market, delineating the major competitors in the space, including Iqvia (NYSE: IQV), Icon (NASDAQ: ICLR), PPD, Medpace (NASDAQ: MEDP) and Syneos (NASDAQ: SYNH)
  • Overall market growth assessment breaking down key criteria – book-to-bills, product expansion, market shares and price wars
  • Pre-clinical and clinical research capabilities and associated funding environments, differentiating on the basis of competency and required assets
  • Consolidation and divestiture activity, especially following Labcorp’s (NYSE: LH) divestiture of Covance, discussing areas of potential M&A – pharmacovigilance, health economics, clinical trial design and tech solutions
  • 6-12-month market outlook, outlining near-term headwinds/tailwinds, R&D growth opportunities and therapeutic clinical advancements

Questions

For access to this and thousands of other Transcripts, request a free trial

Request A Demo